FierceHealthcareFierceHealthITFierceHealthFinanceFierceEMRHospital ImpactFierceMobileHealthcare   FiercePharma

HHS plans infection-control initiative

Tools
Tags
methicillin-resistant Staphylococcus aureus (MRSA)
Infection Prevention
Hospital Acquired Infection
Department of Health and Human Services (HHS)

HHS officials said last week that they're planning to roll out a national action plan focused on hospital-acquired infection control. Their plan was developed in response to a GAO report criticizing HHS for a lack of centralized infection-control initiatives, said Don Wright, a physician who serves as principal deputy assistant secretary for health at HHS, speaking at the Joint Commission's 2008 Annual Infection Prevention and Control Conference.

The plan is focused on four infections patients typically contract in hospitals, including catheter-associated urinary-tract infections, surgical-site infections, bloodstream infections and ventilator-associated pneumonia. It will also include efforts to reduce the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff) in hospitals.

The plan specifies that work will be done by five groups led by various HHS agencies. This includes a prevention-and-implementation group, which will create a list of processes hospitals should follow to prevent key infections. It will also include a research group, which will develop programs to round out HHS's knowledge-base; an information-systems group, intended to clarify infection definitions, standardize measurements and create interoperability between HHS systems; and an outreach group responsible for providing public information on the effort.

To learn more about HHS's plans:
- read this Modern Healthcare piece

Related Articles:
GAO says gov't needs to create HAI prevention standards
MA hospital-acquired infections cost millions
VHA program fights hospital-acquired infections
Blue Shield of California Foundation expands hospital-infection program

Comments

The nosocomiale infections statistic will not help. This money should be used to develop non-toxic Apofix, which boosts the immunity sublingually at 5 micrograms per week. All people with the degenerative diseases are immunosuppressed. I am looking for an investment in my company Axanton for Apofix development. The efficient immunity leads to prevention the degenerative diseases and infections.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.